Market Closed -
Other stock markets
|
After market 19:05:03 | |||
10.27 EUR | -2.00% | 10.24 | -0.24% |
05-14 | Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment | MT |
05-14 | Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease | CI |
Sales 2024 * | 874M 950M 75B | Sales 2025 * | 1.04B 1.13B 89.02B | Capitalization | 1.86B 2.02B 159B |
---|---|---|---|---|---|
Net income 2024 * | -29M -31.53M -2.49B | Net income 2025 * | 34M 36.97M 2.92B | EV / Sales 2024 * | 2.43 x |
Net Debt 2024 * | 269M 292M 23.08B | Net Debt 2025 * | 142M 154M 12.16B | EV / Sales 2025 * | 1.93 x |
P/E ratio 2024 * |
-63.1
x | P/E ratio 2025 * |
33.2
x | Employees | 5,061 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
1 day | -2.24% | ||
1 week | +6.48% | ||
Current month | +5.44% | ||
1 month | -22.37% | ||
3 months | -24.84% | ||
6 months | -43.73% | ||
Current year | -51.74% |
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 06/02/23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 30/04/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 18/06/19 |
Chairman | 63 | 16/06/14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 17 M€ | -.--% | - | |
2.59% | 202 M€ | -.--% | ||
0.21% | 79 M€ | -.--% | ||
0.15% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
16/05/24 | 10.27 | -2.00% | 1 238 389 |
15/05/24 | 10.48 | +2.04% | 1,405,214 |
14/05/24 | 10.27 | +3.01% | 1,830,577 |
13/05/24 | 9.97 | +4.73% | 2,080,093 |
10/05/24 | 9.52 | -1.30% | 1,141,574 |
Delayed Quote Xetra, May 16, 2024 at 04:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.74% | 2.02B | |
+32.75% | 49.46B | |
+1.76% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.97% | 26.61B | |
-22.52% | 18.64B | |
+8.29% | 13.16B | |
+31.00% | 12.55B | |
+24.25% | 12.1B |
- Stock Market
- Equities
- EVT Stock